TheraRadar

Debiopharm

Pre-Approval PRO BETA
43
Total Trials
8
Phase 3
12
Phase 2
7
Recruiting
299
Score

Pipeline by Phase

Phase 3
8
Phase 2
12
Phase 1
26

Therapeutic Focus

Hepatitis C Bacterial Infections Solid Tumors Prostate Cancer Advanced Solid Tumors

Clinical Trials (43)

NCT06930625 Phase 3 RECRUITING

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

Started: 11/26/2025

NCT06129539 Phase 3 ACTIVE NOT RECRUITING

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)

Started: 7/31/2024

NCT01467882 Phase 3 COMPLETED

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Started: 4/1/2012

NCT01446250 Phase 3 TERMINATED

Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1

Started: 12/1/2011

NCT01318694 Phase 3 COMPLETED

Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

Started: 3/1/2011

NCT02753699 Phase 3 COMPLETED

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Started: 12/1/2011

NCT01500772 Phase 3 TERMINATED

Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

Started: 3/1/2012

NCT01656161 Phase 3 COMPLETED

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Started: 7/1/2012

NCT06395753 Phase 2 ACTIVE NOT RECRUITING

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

Started: 5/23/2024

NCT03723551 Phase 2 TERMINATED

Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus

Started: 2/20/2019

NCT02564744 Phase 2 COMPLETED

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Started: 6/5/2016

NCT03834220 Phase 2 TERMINATED

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Started: 3/22/2019

NCT02426918 Phase 2 COMPLETED

Study of Debio 1450 for Bacterial Skin Infections

Started: 5/1/2015

NCT02094443 Phase 2 COMPLETED

Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

Started: 3/1/2014

NCT01215643 Phase 2 COMPLETED

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

Started: 10/1/2010

NCT01183169 Phase 2 COMPLETED

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

Started: 8/1/2010

NCT00838253 Phase 2 WITHDRAWN

Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients

Started: 6/1/2009

NCT05765812 Phase 1 RECRUITING

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Started: 5/15/2023

NCT07035769 Phase 1 RECRUITING

A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy Adults

Started: 6/18/2025

NCT04855656 Phase 1 RECRUITING

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

Started: 4/30/2021

NCT06969430 Phase 1 RECRUITING

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Started: 5/30/2025

NCT05815160 Phase 1 TERMINATED

Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy

Started: 5/2/2023

NCT05109975 Phase 1 TERMINATED

A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

Started: 11/5/2021

NCT05147350 Phase 1 TERMINATED

Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

Started: 8/9/2022

NCT03968653 Phase 1 TERMINATED

Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors

Started: 7/30/2019

NCT05147272 Phase 1 TERMINATED

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

Started: 12/16/2021

NCT05364944 Phase 1 TERMINATED

A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Started: 5/18/2022

NCT04122625 Phase 1 COMPLETED

Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143

Started: 4/26/2019

NCT03270176 Phase 1 COMPLETED

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

Started: 10/10/2017

NCT04962724 Phase 1 COMPLETED

A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants

Started: 8/2/2021

NCT01948297 Phase 1 TERMINATED

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

Started: 8/1/2013

NCT01078649 Phase 1 COMPLETED

Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

Started: 3/29/2010

NCT02726438 Phase 1 COMPLETED

Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery

Started: 4/1/2016

NCT03209648 Phase 1 COMPLETED

A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects

Started: 6/14/2017

NCT01975337 Phase 1 COMPLETED

Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects

Started: 8/1/2013

NCT01860326 Phase 1 COMPLETED

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

Started: 3/1/2011

NCT01930292 Phase 1 TERMINATED

Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies

Started: 4/1/2013

NCT02595203 Phase 1 COMPLETED

Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects

Started: 11/1/2015

NCT01714037 Phase 1 TERMINATED

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]

Started: 8/1/2012

NCT02214433 Phase 1 COMPLETED

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

Started: 8/1/2014

NCT00869115 Phase 1 WITHDRAWN

Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure

Started: 6/1/2009

NCT02162199 Phase 1 COMPLETED

A Single Dose Study of Debio 1450 in Healthy Subjects

Started: 6/1/2014

NCT01168752 Phase 1 COMPLETED

Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma

Started: 4/1/2010

Drug Candidates

Debio 0123 Debio 4228 Debio 4126 Debio 4326 Debio 1453P Lunresertib RP-3500 Debio0123 Debio 1562M RP-6306 (oral PKMYT1 inhibitor)
Activity Status: Active
Last Trial Started: 11/26/2025
Last Trial Ended: 4/24/2026
Trials (12 months): 1
Completed Trials: 21
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.